L. C. , a exercé des fonctions de consultant auprès de Novartis Pharma et a participé en tant qu'orateur à des colloques organisés par Novartis Pharma et Ménarini, investigateur dans des essais cliniques thérapeutiques financés par les laboratoires Amgen, 2014.

N. Roche, ;. Sanofi, /. Boehringer, G. Pfizer, I. Médical et al., hôtel, repas) à l'occasion de déplacements pour des congrès médicaux par AstraZeneca, Il a participé en tant qu'orateur à des colloques et symposiums organisés par Novartis, 2014.

. Références,

G. D'amato, C. Vitale, A. Molino, A. Stanziola, A. Sanduzzi et al., Asthmarelated deaths, Multidiscip Respir Med, vol.11, p.37, 2016.

D. Mcacf, Asthma in France: a review of descriptive epidemiological data, Rev Mal Respir, vol.27, issue.2, pp.151-160, 2009.

H. K. Reddel, E. D. Bateman, A. Becker, L. P. Boulet, A. A. Cruz et al., A summary of the new GINA strategy: a roadmap to asthma control, Eur Respir J, vol.46, issue.3, pp.622-661, 2015.

K. F. Chung, S. E. Wenzel, J. L. Brozek, A. Bush, M. Castro et al., International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, Eur Respir J, vol.43, issue.2, pp.343-73, 2014.

W. C. Moore, E. R. Bleecker, D. Curran-everett, S. C. Erzurum, B. T. Ameredes et al., Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program, J Allergy Clin Immunol, vol.119, issue.2, pp.405-418, 2007.

S. Lane, J. Molina, and T. Plusa, An international observational prospective study to determine the cost of asthma exacerbations (COAX), Respir Med, vol.100, issue.3, pp.434-50, 2006.

E. Israel and H. K. Reddel, Severe and difficult-to-treat asthma in adults, N Engl J Med, vol.377, issue.10, pp.965-76, 2017.

W. C. Moore, D. A. Meyers, S. E. Wenzel, W. G. Teague, H. Li et al., Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program, Am J Respir Crit Care Med, vol.181, issue.4, pp.315-338, 2010.

P. Haldar, I. D. Pavord, D. E. Shaw, M. A. Berry, M. Thomas et al., Cluster analysis and clinical asthma phenotypes, Am J Respir Crit Care Med, vol.178, issue.3, pp.218-242, 2008.
DOI : 10.1164/rccm.200711-1754oc

URL : http://europepmc.org/articles/pmc3992366?pdf=render

A. Bourdin, N. Molinari, I. Vachier, M. Varrin, G. Marin et al., Prognostic value of cluster analysis of severe asthma phenotypes, J Allergy Clin Immunol, vol.134, issue.5, pp.1043-50, 2014.

T. F. Carr, A. A. Zeki, and M. Kraft, Eosinophilic and noneosinophilic asthma, Am J Respir Crit Care Med, vol.197, issue.1, pp.22-37, 2018.
DOI : 10.1164/rccm.201611-2232pp

I. D. Pavord, R. Beasley, A. Agusti, G. P. Anderson, E. Bel et al., After asthma: redefining airways diseases, Lancet, vol.391, pp.350-400, 2018.
DOI : 10.1016/s0140-6736(17)30879-6

URL : http://spiral.imperial.ac.uk/bitstream/10044/1/51311/6/THELANCET-D-16-01609R2.pdf

B. N. Lambrecht, D. Veerman, M. Coyle, A. J. Gutierrez-ramos, J. C. Thielemans et al., Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation, J Clin Invest, vol.106, issue.4, pp.551-560, 2000.
DOI : 10.1172/jci8107

URL : http://www.jci.org/articles/view/8107/files/pdf

A. W. Mould, A. J. Ramsay, K. I. Matthaei, I. G. Young, M. E. Rothenberg et al., The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity, J Immunol, vol.164, issue.4, pp.2142-50, 2000.

J. P. Rajan, N. E. Wineinger, D. D. Stevenson, and A. A. White, Prevalence of aspirinexacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature, J Allergy Clin Immunol, vol.135, issue.3, 2015.

K. Mascia, T. Haselkorn, Y. M. Deniz, D. P. Miller, E. R. Bleecker et al., Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma, J Allergy Clin Immunol, vol.116, issue.5, pp.970-975, 2005.

S. G. Smith, R. Chen, M. Kjarsgaard, C. Huang, J. P. Oliveria et al., Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia, J Allergy Clin Immunol, vol.137, issue.1, 2016.

P. G. Woodruff, B. Modrek, D. F. Choy, G. Jia, A. R. Abbas et al., T-helper type 2-driven inflammation defines major subphenotypes of asthma, Am J Respir Crit Care Med, vol.180, issue.5, pp.388-95, 2009.

T. Volmer, T. Effenberger, C. Trautner, and R. Buhl, Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature, Eur Respir J, vol.52, issue.4, 2018.

W. C. Moore, A. T. Hastie, X. Li, H. Li, W. W. Busse et al., Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis, J Allergy Clin Immunol, vol.133, issue.6, 2014.
DOI : 10.1016/j.jaci.2013.10.011

URL : http://europepmc.org/articles/pmc4040309?pdf=render

R. H. Green, C. E. Brightling, G. Woltmann, D. Parker, A. J. Wardlaw et al., Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids, Thorax, vol.57, issue.10, pp.875-884, 2002.

J. Chesne, F. Braza, G. Mahay, S. Brouard, M. Aronica et al., IL-17 in severe asthma. Where do we stand?, Am J Respir Crit Care Med, vol.190, issue.10, pp.1094-101, 2014.

I. Bara, A. Ozier, J. M. Tunon-de-lara, R. Marthan, and P. Berger, Pathophysiology of bronchial smooth muscle remodelling in asthma, Eur Respir J, vol.36, issue.5, pp.1174-84, 2010.

P. J. Chang, C. Michaeloudes, J. Zhu, N. Shaikh, J. Baker et al., Impaired nuclear translocation of the glucocorticoid receptor in corticosteroidinsensitive airway smooth muscle in severe asthma, Am J Respir Crit Care Med, vol.191, issue.1, pp.54-62, 2015.

C. S. Kuo, S. Pavlidis, M. Loza, F. Baribaud, A. Rowe et al., A Transcriptomedriven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED, Am J Respir Crit Care Med, vol.195, issue.4, pp.443-55, 2017.

D. Lefaudeux, D. Meulder, B. Loza, M. J. Peffer, N. Rowe et al., U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, J Allergy Clin Immunol, vol.139, issue.6, pp.1797-807, 2017.

C. S. Kuo, S. Pavlidis, M. Loza, F. Baribaud, A. Rowe et al., T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED, Eur Respir J, vol.49, issue.2, 2017.

S. J. Wilson, J. A. Ward, A. R. Sousa, J. Corfield, A. T. Bansal et al., Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study, Eur Respir J, vol.48, issue.5, pp.1307-1326, 2016.

N. Turan, M. J. Edwards, S. Bates, D. Shaw, K. F. Chung et al., IL-6 pathway upregulation in subgroup of severe asthma is associated with neutrophilia and poor lung function, Clin Exp Allergy, vol.48, issue.4, pp.475-483, 2018.

C. Rossios, S. Pavlidis, U. Hoda, C. H. Kuo, C. Wiegman et al., Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, J Allergy Clin Immunol, vol.141, issue.2, pp.560-70, 2018.

D. E. Shaw, A. R. Sousa, S. J. Fowler, L. J. Fleming, G. Roberts et al., Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort, Eur Respir J, vol.46, issue.5, pp.1308-1329, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01969506

R. Emma, A. T. Bansal, J. Kolmert, C. E. Wheelock, S. E. Dahlen et al., Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort, PLoS One, vol.13, issue.9, 2018.

K. Takahashi, S. Pavlidis, F. Ng-kee-kwong, U. Hoda, C. Rossios et al., Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis, Eur Respir J, vol.51, issue.5, 2018.

G. Brusselle, A. Michils, R. Louis, L. Dupont, B. Van-de-maele et al., Reallife" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study, Respir Med, vol.103, issue.11, pp.1633-1675, 2009.

M. Molimard, R. Buhl, N. R. , L. Gros, V. Thielen et al., Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data, Respir Med, vol.104, issue.9, pp.1381-1386, 2010.

M. Humbert, C. Taille, M. L. , L. Gros, V. Just et al., Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study, Eur Respir J, vol.51, issue.5, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01962427

H. G. Ortega, M. C. Liu, I. D. Pavord, G. G. Brusselle, J. M. Fitzgerald et al., Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med, vol.371, issue.13, pp.1198-207, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01785638

E. H. Bel, S. E. Wenzel, P. J. Thompson, C. M. Prazma, O. N. Keene et al., Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, N Engl J Med, vol.371, issue.13, pp.1189-97, 2014.

N. Lugogo, C. Domingo, P. Chanez, R. Leigh, M. J. Gilson et al., Longterm efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study, Clin Ther, vol.38, issue.9, 2016.

A. Magnan, A. Bourdin, C. M. Prazma, F. C. Albers, R. G. Price et al., Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1379, 2016.
DOI : 10.1111/all.12914

URL : https://hal.archives-ouvertes.fr/hal-01785638

P. Haldar, C. E. Brightling, A. Singapuri, B. Hargadon, S. Gupta et al., Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis, J Allergy Clin Immunol, vol.133, issue.3, pp.921-924, 2014.

M. Castro, J. Zangrilli, M. E. Wechsler, E. D. Bateman, G. G. Brusselle et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, Lancet Respir Med, vol.3, issue.5, pp.355-66, 2015.
DOI : 10.1016/s2213-2600(15)00042-9

L. Bjermer, C. Lemiere, J. Maspero, S. Weiss, J. Zangrilli et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study, Chest, vol.150, issue.4, pp.789-98, 2016.
DOI : 10.1016/j.chest.2016.03.032

URL : https://doi.org/10.1016/j.chest.2016.03.032

K. Murphy, J. Jacobs, L. Bjermer, J. M. Fahrenholz, Y. Shalit et al., Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma, J Allergy Clin Immunol Pract, vol.5, issue.6, 2017.

E. R. Bleecker, J. M. Fitzgerald, P. Chanez, A. Papi, S. F. Weinstein et al., Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2115-2142, 2016.

J. M. Fitzgerald, E. R. Bleecker, P. Nair, S. Korn, K. Ohta et al., Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2128-2169, 2016.

P. Nair, S. Wenzel, K. F. Rabe, A. Bourdin, N. L. Lugogo et al., Oral glucocorticoid-sparing effect of benralizumab in severe asthma, N Engl J Med, vol.376, issue.25, pp.2448-58, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01761510

Y. Cabon, N. Molinari, G. Marin, I. Vachier, A. S. Gamez et al., Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials, Clin Exp Allergy, vol.47, issue.1, pp.129-167, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01821350

S. Wenzel, M. Castro, J. Corren, J. Maspero, L. Wang et al., Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial, Lancet, vol.388, pp.31-44, 2016.

M. Castro, J. Corren, I. D. Pavord, J. Maspero, S. Wenzel et al., Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma, N Engl J Med, vol.378, issue.26, pp.2486-96, 2018.
DOI : 10.1056/nejmoa1804092

K. F. Rabe, P. Nair, G. Brusselle, J. F. Maspero, M. Castro et al., Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma, N Engl J Med, vol.378, issue.26, pp.2475-85, 2018.

R. A. Panettieri, U. Sjobring, A. Peterffy, P. Wessman, K. Bowen et al., Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials, Lancet Respir Med, vol.6, issue.7, pp.511-536, 2018.
DOI : 10.1016/s2213-2600(18)30184-x

URL : https://lra.le.ac.uk/bitstream/2381/42346/2/Stratos%201%20and%202%20Brightling%20accepted%20pre-publication%20version.pdf

N. A. Hanania, P. Korenblat, K. R. Chapman, E. D. Bateman, P. Kopecky et al., Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials, Lancet Respir Med, vol.4, issue.10, pp.781-96, 2016.

W. W. Busse, G. G. Brusselle, S. Korn, P. Kuna, A. Magnan et al., Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
DOI : 10.1183/13993003.00948-2018

, Eur Respir J, vol.53, issue.2, 2019.

S. Gonem, R. Berair, A. Singapuri, R. Hartley, M. Laurencin et al., Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallelgroup, placebo-controlled trial, Lancet Respir Med, vol.4, issue.9, pp.699-707, 2016.

J. Corren, J. R. Parnes, L. Wang, M. Mo, S. L. Roseti et al., Tezepelumab in adults with uncontrolled asthma, N Engl J Med, vol.377, issue.10, pp.936-982, 2017.
DOI : 10.1056/nejmoa1704064

J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson, Clarithromycin targets neutrophilic airway inflammation in refractory asthma, Am J Respir Crit Care Med, vol.177, issue.2, pp.148-55, 2008.

G. G. Brusselle, C. Vanderstichele, P. Jordens, R. Deman, H. Slabbynck et al., Azithromycin for prevention of exacerbations in severe asthma (AZI-SAST): a multicentre randomised double-blind placebo-controlled trial, Thorax, vol.68, issue.4, pp.322-331, 2013.

M. Castro, A. S. Rubin, M. Laviolette, J. Fiterman, M. De-andrade-lima et al., Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial, Am J Respir Crit Care Med, vol.181, issue.2, pp.116-140, 2010.

M. E. Wechsler, M. Laviolette, A. S. Rubin, J. Fiterman, J. R. Lapa-e-silva et al., Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma, J Allergy Clin Immunol, vol.132, issue.6, pp.1295-302, 2014.

N. C. Thomson, A. S. Rubin, R. M. Niven, P. A. Corris, H. C. Siersted et al., Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial, BMC Pulm Med, vol.11, issue.8, 2011.

M. Pretolani, A. Bergqvist, G. Thabut, M. C. Dombret, D. Knapp et al., Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations, J Allergy Clin Immunol, vol.139, issue.4, pp.1176-85, 2016.

M. Pretolani, M. C. Dombret, G. Thabut, D. Knap, F. Hamidi et al., Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma, Am J Respir Crit Care Med, vol.190, issue.12, pp.1452-1456, 2014.